Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates include INOpulse, a pulsatile nitric oxide delivery device, which has completed Phase II clinical trials for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases; and bioabsorbable cardiac matrix, a medical device for the prevention of congestive heart failure. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
http://www.priceseries.com/trade/BLPH-Bellerophon-Therapeutics-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2017092720171016.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments